US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.40 — a beat of 12.5%.
Analysts rate Ocular Therapeutix Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $27.09.
| Fund | Stake |
|---|---|
| FMR Inc | 14.96% |
| Deep Track Capital, LP | 8.96% |
| BlackRock Inc | 8.82% |
| venBio Select Advisor LLC | 5.71% |
| SUMMER ROAD LLC | 5.56% |
| VR Adviser, LLC | 4.71% |
| Vanguard Capital Management, LLC | 4.02% |
| T. Rowe Price Associates, Inc. | 3.47% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Ocular Therapeutix reported that Chief Strategy Officer Sanjay Nayak, M.B.B.S., Ph.D., resigned from the company. • His resignati | 2026-10-16 |
| Quarterly report · Q2 2026 OCULAR THERAPEUTIX, INC. – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $598.6 million as of June 30, 2026 (down from $737 | 2026-08-03 |
| Results announced · Q3 2026 OCULAR THERAPEUTIX Q2 2026 FINANCIAL RESULTS – RETAIL INVESTOR SUMMARY HEADLINE NUMBERS • Cash balance: $598.6 million as of June 30, 2026 • Expecte | 2026-08-03 |
| Board / officer change · Q2 2026 OCULAR THERAPEUTIX, INC. - FORM 8-K SUMMARY Reporting Date: June 10, 2026 --- HEADLINE NUMBERS • Stock Incentive Plan increase: 10,000,000 addition | 2026-06-12 |
| Quarterly report · Q1 2026 OCULAR THERAPEUTIX, INC. - Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $666.7 million as of March 31, 2026 (down from $7 | 2026-05-05 |
| Results announced · Q2 2026 OCULAR THERAPEUTIX Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash balance of $666.7 million as of March 31, 2026 • Estimated cash runway | 2026-05-05 |
| Proxy statement · Q2 2026 OCULAR THERAPEUTIX, INC. – PROXY STATEMENT SUMMARY CEO COMPENSATION • CEO Total Pay 2025: $5,402,752 (Dr. Pravin U. Dugel, who became President and | 2026-04-30 |
| Reg FD disclosure · Q1 2026 OCULAR THERAPEUTIX, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Ocular Therapeutix, Inc. (Nasdaq: OCUL) • Headquarters: Bedford, MA • Report | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Plan to submit new drug application for wet AMD treatment based on year 1 data Ocular Therapeutix announced that it plans to submit a new drug application (NDA) to the FDA for AXPAXLI (OTX-TKI), its wet age-related macular degeneration (wet AMD) treatment candidate, ba | 2025-12-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ocular Therapeutix Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.